A Cancer Research UK Phase I Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage III and IV Pancreatic Cancer

Trial Profile

A Cancer Research UK Phase I Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage III and IV Pancreatic Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Gemcitabine (Primary) ; MK 0752 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Feb 2018 Results assessing tolerability and efficacy of MK-0752 in combination with gemcitabine in patients with stage III and IV pancreatic cancer, were published in the British Journal of Cancer.
    • 10 Jun 2017 Biomarkers information updated
    • 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top